Roth Capital Raises ANI Pharmaceuticals Price Target Following 3Q14 Results
Roth Capital analyst Scott Henry reaffirmed a Buy rating on ANI Pharmaceuticals (NASDAQ:ANIP) and increased his price target to $55, following the company’s third-quarter results, posting revenues of $17.4 million, which was well ahead of Roth’s $14.6M target.
Henry wrote, “ANIP reported strong 3Q14 results that beat top and bottom line forecasts. The driver of the positive results appeared the recent acquisitions of Lithobid and Vancocin. We expect this upside to continue, and we have upped our 2015-16 EPS targets to $2.80 and $3.40 (from $2.00 and $2.50)”.
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Scott Henry has a total average return of 14.8% and a 55.2% success rate. Henry has a 35.7% average return when recommending ANIP, and is ranked #266 out of 3358 analysts.